Tetrapeptides as potent protease inhibitors of Hepatitis C Virus full-length NS3 (protease-helicase/NTPase).

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Bioorganic & Medicinal Chemistry

• Publication date

  2002-12-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/S0968-0896(02)00310-3PMID 12413843
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Designing non-peptide peptidomimetics in the 21st century: inhibitors targeting conformational ensembles.

  2002cited by this paper
• Expression and purification of recombinant full-length NS3 protease-helicase from a new variant of Hepatitis C virus.

  2002cited by this paper
• A designed P1 cysteine mimetic for covalent and non-covalent inhibitors of HCV NS3 protease.

  2002cited by this paper
• Azapeptides as inhibitors of the hepatitis C virus NS3 serine protease.

  2002cited by this paper
• Evolution, synthesis and SAR of tripeptide alpha-ketoacid inhibitors of the hepatitis C virus NS3/NS4A serine protease.

  2002cited by this paper
• Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain.

  2001cited by this paper
• Emerging therapies for hepatitis C virus infection

  2001cited by this paper
• Role of charged residues in the catalytic mechanism of hepatitis C virus NS3 protease: electrostatic precollision guidance and transition-state stabilization.

  2001cited by this paper
• Solid-phase synthesis of peptidomimetic inhibitors for the hepatitis C virus NS3 protease.

  2001cited by this paper
• The identification of α-ketoamides as potent inhibitors of hepatitis c virus nS3-4a proteinase

  2001cited by this paper
• Recent advances in the molecular biology of hepatitis C virus.

  2001cited by this paper
• The identification of alpha-ketoamides as potent inhibitors of hepatitis C virus NS3-4A proteinase.

  2001cited by this paper
• Hepatitis C virus protease inhibitors: current progress and future challenges.

  2001cited by this paper
• Solid phase synthesis of peptide aldehyde protease inhibitors. Probing the proteolytic sites of hepatitis C virus polyprotein

  2000cited by this paper
• Alpha-ketoamides, alpha-ketoesters and alpha-diketones as HCV NS3 protease inhibitors.

  2000cited by this paper
• Alpha-ketoacids are potent slow binding inhibitors of the hepatitis C virus NS3 protease.

  2000cited by this paper
• 1-Aminocyclopropaneboronic acid: synthesis and incorporation into an inhibitor of hepatitis C virus NS3 protease.

  2000cited by this paper
• Structure and function of the hepatitis C virus NS3-NS4A serine proteinase.

  2000cited by this paper
• α-Ketoamides, α-ketoesters and α-diketones as HCV NS3 protease inhibitors

  2000cited by this paper
• Solid phase synthesis of aminoboronic acids: potent inhibitors of the hepatitis C virus NS3 proteinase.

  2000cited by this paper
• Optimization of the P'-region of peptide inhibitors of hepatitis C virus NS3/4A protease.

  2000cited by this paper
• Novel Approaches to the Treatment of Hepatitis C Virus Infection

  2000cited by this paper
• Highly potent and selective peptide-based inhibitors of the hepatitis C virus serine protease: towards smaller inhibitors.

  2000cited by this paper
• Global surveillance and control of hepatitis C

  1999cited by this paper
• The Scientific Challenge of Hepatitis C

  1999cited by this paper
• The NS3/4A proteinase of the hepatitis C virus: unravelling structure and function of an unusual enzyme and a prime target for antiviral therapy

  1999cited by this paper
• The Design and Synthesis of Potent Inhibitors of Hepatitis C Virus NS3–4A Proteinase

  1999cited by this paper
• Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase.

  1999cited by this paper
• Use of a fluorescence plate reader for measuring kinetic parameters with inner filter effect correction.

  1999cited by this paper
• Peptide-based inhibitors of the hepatitis C virus serine protease.

  1998cited by this paper
• Studies on the C-terminal of hexapeptide inhibitors of the hepatitis C virus serine protease.

  1998cited by this paper
• Potent peptide inhibitors of human hepatitis C virus NS3 protease are obtained by optimizing the cleavage products.

  1998cited by this paper
• Product inhibition of the hepatitis C virus NS3 protease.

  1998cited by this paper
• Substrate Specificity of the Hepatitis C Virus Serine Protease NS3*

  1997cited by this paper
• Candidate targets for hepatitis C virus-specific antiviral therapy.

  1997cited by this paper
• Mechanistic role of an NS4A peptide cofactor with the truncated NS3 protease of hepatitis C virus: elucidation of the NS4A stimulatory effect via kinetic analysis and inhibitor mapping.

  1997cited by this paper
• Structure of the hepatitis C virus RNA helicase domain

  1997cited by this paper
• Probing the substrate specificity of hepatitis C virus NS3 serine protease by using synthetic peptides

  1997cited by this paper
• Activity of purified hepatitis C virus protease NS3 on peptide substrates

  1996cited by this paper
• Peptides : synthesis, structures, and applications

  1995cited by this paper
• Macromodel—an integrated software system for modeling organic and bioorganic molecules using molecular mechanics

  1990cited by this paper
• Semianalytical treatment of solvation for molecular mechanics and dynamics

  1990cited by this paper
• Darstellung geschützter peptid-fragmente unter einsatz substituierter triphenylmethyl-harze

  1989cited by this paper
• Aromatic rings act as hydrogen bond acceptors.

  1988cited by this paper
• Amino‐aromatic interactions in proteins

  1986cited by this paper
• An all atom force field for simulations of proteins and nucleic acids

  1986cited by this paper
• A NEW FORCE FIELD FOR MOLECULAR MECHANICAL SIMULATION OF NUCLEIC ACIDS AND PROTEINS

  1984cited by this paper
• Aromatic Rings Act as Hydrogen Bond Acceptors

  year unknowncited by this paper

• Pan-NS3 protease inhibitors of hepatitis C virus based on an R3-elongated pyrazinone scaffold.

  2018cites this paper
• Discovery of pyrazinone based compounds that potently inhibit the drug-resistant enzyme variant R155K of the hepatitis C virus NS3 protease.

  2016cites this paper
• Organocatalyzed asymmetric tandem Michael-cyclization reaction of 4-benzylidene-3-methylpyrazol-5-ones and malononitrile: stereocontrolled construction of pyrano[2,3-c]pyrazole scaffold

  2015cites this paper
• Virtual Screening and Molecular Dynamics Simulations from a Bank of Molecules of the Amazon Region Against Functional NS3-4A Protease-Helicase Enzyme of Hepatitis C Virus

  2015cites this paper
• Achiral pyrazinone-based inhibitors of the hepatitis C virus NS3 protease and drug-resistant variants with elongated substituents directed toward the S2 pocket.

  2014cites this paper
• Vinylated linear P2 pyrimidinyloxyphenylglycine based inhibitors of the HCV NS3/4A protease and corresponding macrocycles.

  2014cites this paper
• Understanding the structural and energetic basis of inhibitor and substrate bound to the full-length NS3/4A: insights from molecular dynamics simulation, binding free energy calculation and network analysis.

  2012cites this paper
• Perspective: the potential of pyrazole-based compounds in medicine

  2012cites this paper
• P2-P1' macrocyclization of P2 phenylglycine based HCV NS3 protease inhibitors using ring-closing metathesis.

  2011cites this paper
• Improved P2 phenylglycine-based hepatitis C virus NS3 protease inhibitors with alkenylic prime-side substituents.

  2010cites this paper
• Discovery of achiral inhibitors of the hepatitis C virus NS3 protease based on 2(1H)-pyrazinones.

  2010cites this paper
• Hepatitis C virus NS3 protease is activated by low concentrations of protease inhibitors.

  2009cites this paper
• Hepatitis C virus NS3 protease inhibitors comprising a novel aromatic P1 moiety.

  2008cites this paper
• Inhibition of hepatitis C virus RNA replicons by peptide aptamers.

  2008cites this paper
• New developments in the discovery of agents to treat hepatitis C.

  2008cites this paper
• Natural occurrence, syntheses, and applications of cyclopropyl-group-containing alpha-amino acids. 1. 1-aminocyclopropanecarboxylic acid and other 2,3-methanoamino acids.

  2007cites this paper
• Evaluation of a diverse set of potential P1 carboxylic acid bioisosteres in hepatitis C virus NS3 protease inhibitors.

  2007cites this paper
• Mathematical Model for Suppression of Subgenomic Hepatitis C Virus RNA Replication in Cell Culture

  2007cites this paper
• Mechanistic studies of electrophilic protease inhibitors of full length hepatic C virus (HCV) NS3

  2007cites this paper
• Resistance Profiling of Hepatitis C Virus Protease Inhibitors using Full-Length NS3

  2007cites this paper
• Novel potent macrocyclic inhibitors of the hepatitis C virus NS3 protease: use of cyclopentane and cyclopentene P2-motifs.

  2007cites this paper
• Phenylglycine as a novel P2 scaffold in hepatitis C virus NS3 protease inhibitors.

  2007cites this paper
• Effects on protease inhibition by modifying of helicase residues in hepatitis C virus nonstructural protein 3

  2007cites this paper
• Synthesis of novel potent hepatitis C virus NS3 protease inhibitors: discovery of 4-hydroxy-cyclopent-2-ene-1,2-dicarboxylic acid as a N-acyl-L-hydroxyproline bioisostere.

  2007cites this paper
• Exploration of acyl sulfonamides as carboxylic acid replacements in protease inhibitors of the hepatitis C virus full-length NS3.

  2006cites this paper
• Potent inhibitors of the hepatitis C virus NS3 protease: use of a novel P2 cyclopentane-derived template.

  2006cites this paper
• Easy-to-execute carbonylations: microwave synthesis of acyl sulfonamides using Mo(CO)(6) as a solid carbon monoxide source.

  2005cites this paper
• Structure-Based Design and Synthesis of Protease Inhibitors Using Cycloalkenes as Proline Bioisosteres and Combinatorial Syntheses of a Targeted Library

  2005cites this paper
• CO: A chemical ontology for identification of functional groups and semantic comparison of small molecules

  2005cites this paper
• HCV NS3 serine protease-neutralizing single-chain antibodies isolated by a novel genetic screen.

  2005cites this paper
• Peptide-Based Inhibitors of Hepatitis C Virus NS3 Serine Protease: Kinetic Aspects and Inhibitor Design

  2004cites this paper
• Structure-activity relationships for the selectivity of hepatitis C virus NS3 protease inhibitors.

  2004cites this paper
• Acyl sulfonamides as potent protease inhibitors of the hepatitis C virus full-Length NS3 (protease-helicase/NTPase): a comparative study of different C-terminals.

  2003cites this paper
• Recent developments in the discovery of hepatitis C virus serine protease inhibitors – towards a new class of antiviral agents?

  2003cites this paper
• Interaction Characteristics of Viral Protease Targets and Inhibitors Perspectives for Drug Discovery and Development of Model Systems

  2003cites this paper
• Inhibitors of hepatitis C virus NS3.4A protease 1. Non-charged tetrapeptide variants.

  2003cites this paper
• Polysubstituted pyrazoles, part 5. Synthesis of new 1-(4-chlorophenyl)-4-hydroxy-1H-pyrazole-3-carboxylic acid hydrazide analogs and some derived ring systems. A novel class of potential antitumor and anti-HCV agents.

  2003cites this paper
• Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 282 Design and Synthesis of Hepatitis C Virus NS3 Protease Inhibitors

  2003cites this paper
• Peptide-based inhibitors of hepatitis C virus full-length NS3 (protease-helicase/NTPase): model compounds towards small molecule inhibitors.

  2003cites this paper